IRTA1 and MNDA Expression in Marginal Zone Lymphoma: Utility in Differential Diagnosis and Implications for Classification. Issue 3 (20th October 2018)

• Record Type: Journal Article
• Authors: Wang, Zhen; Cook, James R
• Is Part Of: American journal of clinical pathology. Volume 151:Issue 3(2019)
• Page Start: 337
• Page End: 343
• Publication Date: 2018-10-20
• Subjects: IRTA1 -- MNDA -- Marginal zone lymphoma; Diagnosis, Laboratory -- Periodicals; Pathology -- Periodicals; 616.07
• DOI: 10.1093/ajcp/aqy144
• Languages: English
• ISSNs: 0002-9173

Abstract

Abstract: Objectives: To evaluate the clinical utility of immune receptor translocation-associated protein 1 (IRTA1) and myeloid nuclear differentiation antigen (MNDA) expression in the diagnosis and classification of marginal zone lymphomas (MZLs). Methods: IRTA1 was examined using a novel RNA in situ hybridization assay and MNDA expression determined by immunohistochemistry in 127 small B-cell neoplasms, including 80 cases of MZL. Results: IRTA1 expression was detected in 31 (42%) of 74 MZLs vs one (2%) of 43 other small B-cell neoplasms ( P < .001). MNDA staining was positive in 51 (64%) of 79 MZLs vs 21 (45%) of 46 non-MZLs ( P = .06). MNDA expression was particularly uncommon in follicular lymphoma (3/14, 21%; P = .003 vs MZL). There was no association between MNDA and IRTA1 expression and the presence of monocytoid cytology. IRTA1 expression was less frequent in cases with a diffuse growth pattern. Conclusions: IRTA1 and MNDA are useful markers in the differential diagnosis of MZLs.